25-Year old newly infected patient with a triple-class-drug-resistant HI-virus in Switzerland;25-Jähriger therapienaiver patient mit einem dreiklassenresistenten HI-virus

Praxis

Volumn 92, Issue 13, 2003, Pages 601-605

  Hasse, Barbara ^a   Hummel, Y ^a   Boni J ^b   Schupbach J ^b   Flepp, M ^a   Gunthard H F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Nationales Zentrum für Retroviren   (Switzerland)

Author keywords

Antiretroviral therapy; Drug resistance; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEW DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUCLEOTIDE SEQUENCE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; DRUGS, INVESTIGATIONAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE;

EID: 0041511700     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.92.13.601     Document Type: Article

References (25)

1. Egger M., Hirschel B., Francioli P., et al. Impact of new antiretroviral treatment in HIV infected patients in Switzerland: prospective mulicenter study. Swiss HIV Cohort Study. BMJ; 315(7117):1194-1199,1997. (Pubitemid 27478210)
2. Deeks SG., Barbour JD., Martin JN., Swanson MS., Grant RM. Sustained Cd4+ T cell response after virologic failure of protease inhibitor based regimens in patients with human immuno deficiency infection. J Infect Dis;181:946-953,2000. (Pubitemid 30194478)
3. Ledergerber B., Egger M., Opravil M., et al. for the Swiss HIV Cohort Study. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet;353:863-868,1999. (Pubitemid 29126872)
4. Lorenzi P., Opravil M., Hirschel B., et al. Impact of drug resistance mutations on virologic response to salvage therapy: Swiss HIV Cohort Study. AIDS;13; F17-F21,1999. (Pubitemid 29050401)
5. Resistance testing recommended in new IAS-USA guidelines. AIDS Treat News;343:3-4,2000.
6. Carpenter CC., Cooper DA., Fischl MA., Gatell MA., Gazzard BG., et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society USA Panel. JAMA; 283(3):381-390,2000. (Pubitemid 30051757)
7. British HIV Association (BHIVA) guidelines for treatment of HIV-infected adults with antiretroviral therapy HIV Med;2(4):276-313,2001.
8. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management recommendations for the European setting. The Euro Guidelines Group for HIV resistance. AIDS;15(3)309-320,2001.
9. Larder BA., Darby G., Richmann DD., et al. HIV with reduced sensitivity to zidovudine(AZT) isolated during prolonged therapy. Science; 243(4899):1731-1734,1989. (Pubitemid 19106971)
10. Angaro G., Monno I., Appice A., et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts (Letter). AIDS;8:1013-1014,1994 (Pubitemid 24206616)
11. Grant RM., Hecht FM., Warmerdam M., et al. Time trends in primary HIV-1 Drug resistance among recently infected persons; JAMA;288:181-188,2002. (Pubitemid 34755278)
12. Trachtenberg JD., Sande MA. Emerging resistance to nonnucleoside reverse transcriptase inhibitors, a warning and a challenge (Editorial). JAMA, 288: 239-241,2002. (Pubitemid 34755285)
13. Yerly S., Vora S., Rizzardi P., et al., Acute HIV infection: impact on the spread of HIV and transmission of drug resistance; AIDS;15:2287-2292,2001. (Pubitemid 34059836)
14. Yerly S., Kaiser L., Race E., Bru JP., Clavel F., Perrin L. Transmission of antiretroviral-drug resistant HIV-1 variants. Lancet;354:729-733,1999. (Pubitemid 29407396)
15. Little SJ., Daar ES., D'Aquila RT., et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA;282:1142-1149, 1999. (Pubitemid 29441958)
16. Little SJ., Holte S., Routy J-P., et al., Antiretroviral-drug resistance among patients recently infected with HIV; N Engl J Med; 347:385-384,2002.
17. Shafer RW. Genotypic Testing for Human immunodeficincy Virus Type 1 Drug Resistance. Clinical Microbiology Reviews;247-277,2002. (Pubitemid 34303765)
18. Daar ES., Little SJ., Pitt J., et al. Diagnosis of Primary HIV-1 Infection. Ann Intern Med;134:25-29,2001. (Pubitemid 32037340)
19. De Ronde A., Schuurman R., Goudsmith J., van den Hoek A., Boucher C. First Case of new infection with zidovudine-resistant HIV-1 among prospectively drug-users and and homosexual men in Amsterdam, the Netherlands. AIDS;10, 231-232,1996. (Pubitemid 26056020)
20. Johnson VA., Petropulos CJ., Woods CR., et al. Vertical transmission of multidrug resistant human immunodeficiency virus typ 1 (HIV-1) and continued evolution of drug resistance in a HIV-1 infected infant. J Infect Dis; 183:1688-1693,2001. (Pubitemid 32466710)
21. Böni J., Pyra H., Gebhardt M., et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir immune Defic Syndr;22:174-179,1999.
22. Yeni P., Hammer SM., Carpenter CJ., Cooper DA., et al. Antiretroviral treatment for Adult HIV-Infection in 2002. JAMA;288:222-235,2002.
23. Subkommission der Eidg. Kommission für Aids-Fragen (EKAF): HIV-1-Resistenz gegen antiretrovirale Substanzen in der Schweiz - Resistenzteste auch bei Primo- bzw kürzlicher Infektion (dh nach 1997) empfohlen. Bulletin des Bundesamtes für Gesundheit 2000;5: 104-105.
24. Bozzette SA., Berry SH., Duan N., et al. The care of HIV-infected adults in the United States. N Engl J Med;339:1897-1904,1998. (Pubitemid 29013934)
25. Little SJ., Daar ES., Holte S., et al. Persistence of transmitted drug resistance among subjects with primary HIV-infection not recieving antiretroviral therapy. Abstract. Presented at the 9th Conference of Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002.